Evaluation of a rapid molecular drug-susceptibility test for tuberculosis

New England Journal of Medicine

Volumn 377, Issue 11, 2017, Pages 1043-1054

  Xie, Yingda L ^b   Chakravorty, Soumitesh ^d   Armstrong, Derek T ^c   Hall, Sandra L ^e   Via, Laura E ^b   Song, Taeksun ^f   Yuan, Xing ^j   Mo, Xiaoying ^j   Zhu, Hong ^k   Xu, Peng ^l   Gao, Qian ^l   Lee, Myungsun ^f   Lee, Jongseok ^f   Smith, Laura E ^d   Chen, Ray Y ^b,h   Joh, Joon Sung ^g   Cho, YoungSoo ^h   Liu, Xin ^j   Ruan, Xianglin ^j   Liang, Lili ^j   Dharan, Nila ^d   Cho, Sang Nae ^f,i   Barry, Clifton E ^b,m   Ellner, Jerrold J ^e   Dorman, Susan E ^a,c   Alland, David ^d   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f International Tuberculosis Research Center   (South Korea)

^g National Medical Center   (South Korea)

^h Seoul Metropolitan Seobuk Hospital   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

^j Henan Provincial Chest Hospital   (United States)

^k Tuberculosis Research Collaboration   (China)

^l FUDAN UNIVERSITY   (China)

^m UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ISONIAZID; KANAMYCIN; KATG PROTEIN; MOXIFLOXACIN; OFLOXACIN; AMINOGLYCOSIDE; BACTERIAL DNA; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG SENSITIVITY; EIS GENE; FEMALE; GENE SEQUENCE; GYRA GENE; GYRB GENE; HUMAN; INFORMED CONSENT; INHA GENE; KATG GENE; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RAPID TEST; RRS GENE; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; SPUTUM CULTURE; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; DNA SEQUENCE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MUTATION; POINT OF CARE SYSTEM; PROCEDURES; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; CHINA; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85029577241     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1614915     Document Type: Article

References (38)

1. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. Geneva: World Health Organization, 2016 (http://www.who.int/tb/areas-of-work/drug-resistant-tb/MDRTBguidelines2016.pdf).
2. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377: 1495-505.
3. Cui Z, Wang J, Lu J, Huang X, Hu Z. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis 2011; 11:78.
4. Hazbón MH, Brimacombe M, Boba-dilla del Valle M, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006;50:2640-9.
5. Shi R, Zhang J, Li C, Kazumi Y, Suga-wara I. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006;44: 4566-8.
6. Singh P, Jain A, Dixit P, et al. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. J Antibiot (Tokyo) 2015;68:63-6.
7. Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007;59:860-5.
8. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7(3):e33275.
9. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49: 3192-7.
10. Zhang H, Li D, Zhao L, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013;45: 1255-60.
11. Chakravorty S, Roh SS, Glass J, et al. Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use. J Clin Microbiol 2016;55:183-98.
12. Xpert MTB/RIF. Sunnyvale, CA: Cepheid, February 2015 (package insert).
13. Slayden RA, Barry CE III. The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. Microbes Infect 2000;2:659-69.
14. Xu C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996;174:1127-30.
15. Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-80.
16. Kambli P, Ajbani K, Sadani M, et al. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis (Edinb) 2015;95:137-41.
17. Suzuki Y, Katsukawa C, Tamaru A, et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998;36:1220-5.
18. Kambli P, Ajbani K, Nikam C, et al. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int J Mycobacteriol 2016;5:1-6.
19. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.
20. Gikalo MB, Nosova EY, Krylova LY, Moroz AM. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother 2012;67:2107-9.
21. Kent PT, Kubica GP. Public health my-cobacteriology — a guide for the level III laboratory. Atlanta: Centers for Disease Control, 1985.
22. Laboratory services in tuberculosis control: microscopy. Part 2. Geneva: World Health Organization, 1998.
23. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014 (http://www.who.int/tb/publications/pmdt_companionhandbook/en/).
24. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organization, 2014 (http://www.who.int/tb/publications/tpp_report/en/).
25. Molina-Moya B, Lacoma A, Prat C, et al. Diagnostic accuracy study of multiplex PCR for detecting tuberculosis drug resistance. J Infect 2015;71:220-30.
26. Said HM, Kock MM, Ismail NA, et al. Evaluation of the GenoType MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012;16:104-9.
27. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:1683-9.
28. Tagliani E, Cabibbe AM, Miotto P, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 2015; 53:2961-9.
29. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-72.
30. Tomasicchio M, Theron G, Pietersen E, et al. The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates. Sci Rep 2016;6:17850.
31. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012;90:693-8.
32. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA Mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67:1088-93.
33. Poissy J, Aubry A, Fernandez C, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010;54: 4765-71.
34. Rigouts L, Coeck N, Gumusboga M, et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 2016;71:314-23.
35. van Rie A, Victor TC, Richardson M, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005;172:636-42.
36. Hingley-Wilson SM, Casey R, Connell D, et al. Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection. Emerg Infect Dis 2013;19:1138-41.
37. Brossier F, Guindo D, Pham A, et al. Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 2016; 54:1573-80.
38. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Geneva: World Health Organization, 2016.